Clinical Research Centre, Zhujiang Hospital, Southern Medical University , Guangzhou, Guangdong, China.
Department of Orthopedic Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities , Baise, Guangxi, China.
Expert Opin Pharmacother. 2020 May;21(7):797-809. doi: 10.1080/14656566.2020.1732924. Epub 2020 Feb 26.
Osteoarthritis (OA) is the leading cause of pain, loss of function and disability in the elderly, with the knee being the most impactful joint affected. Currently, there is still no 'cure' in OA treatment.
The authors review the current and emerging therapies for knee OA including traditional OA medications (oral and topical NSAIDs, acetaminophen, and opioids) and emerging treatments including disease-modifying OA drugs. The failures of agents that have been through clinical trials are also summarized. Furthermore, the authors provide their expert perspectives on the future of pharmacotherapy for knee osteoarthritis.
Compared to traditional OA medications, new disease-modifying OA drugs that act by reducing inflammation and increasing cartilage repair show promise to address the unmet need of disease modification. Many of these new drugs, however, are in the preclinical stage. Long-term RCTs are expected to identify the safety and efficacy of novel OA pharmacotherapy medicines.
骨关节炎(OA)是老年人疼痛、功能丧失和残疾的主要原因,膝关节是受影响最严重的关节。目前,OA 治疗仍没有“治愈”方法。
作者回顾了目前和新兴的膝关节 OA 治疗方法,包括传统 OA 药物(口服和局部 NSAIDs、对乙酰氨基酚和阿片类药物)和新兴治疗方法,包括疾病修饰性 OA 药物。作者还总结了已通过临床试验的药物的失败案例。此外,作者还就膝关节骨关节炎的药物治疗未来提供了专业的观点。
与传统 OA 药物相比,通过减少炎症和增加软骨修复来发挥作用的新型疾病修饰性 OA 药物有望满足疾病修饰的未满足需求。然而,这些新药中的许多仍处于临床前阶段。长期 RCT 有望确定新型 OA 药物治疗药物的安全性和疗效。